254. Hospital Costs for Patients with Lower Extremity Cellulitis: A Retrospective Population-Based Study
Session: Poster Abstract Session: Clinical: Skin and Soft Tissue
Thursday, October 5, 2017
Room: Poster Hall CD
  • Challener_2017.pdf (1.1 MB)
  • Background:

    Hospital admissions for non-purulent lower extremity cellulitis (NLEC) are common and can be prolonged and costly. Newer treatment options and prophylactic strategies should be expected to result in cost savings before implementation, but few studies have quantified the cost of conventional treatment.


    Using the Rochester Epidemiology Project, the incidence of NLEC in Olmsted County, MN in 2013 was 176.6 per 100,000 persons. The subset of patients who required hospitalization for NLEC was determined. Hospital admissions were analyzed retrospectively using standardized cost analysis within several relevant categories.


    Thirty-four patients had an average hospital length of stay of 4.7 days. The median total inpatient cost was $7,341. The median cost per day was $2,087. The bulk of this cost was related to room and board. Antibiotics for treatment of NLEC contributed a median cost of $75 per day of hospitalization, and laboratory or imaging tests cost $73 and $44 respectively per day of hospitalization.


    Hospitalizations NLEC can be costly and prolonged, although antibiotic therapy was relatively inexpensive as compared to room and board. Therefore, newer treatment strategies should aim to reduce hospital length of stay and/or avoid inpatient admission to reduce cost.

    Douglas Challener, MD1, Jasmine R. Marcelin, MD2, Sue Visscher, Ph.D.3 and Larry M. Baddour, MD2, (1)Internal Medicine, Mayo Clinic, Rochester, MN, (2)Division of Infectious Diseases, Mayo Clinic, Rochester, MN, (3)Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN


    D. Challener, None

    J. R. Marcelin, None

    S. Visscher, None

    L. M. Baddour, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.